drugset
drugset / Trial / NCT05734898

NKG2D CAR-NK & r/rAML

NCT05734898 ↗

Unknown 30 enrolled Zhejiang University Hangzhou Cheetah Cell Therapeutics Co., Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This trial will explore the maximum tolerated dose（MTD）of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.

Timeline

Start
2023-03
Primary completion
2024-04
Completion
2024-09

Drugs

EvaluationDrugModalityDoseRoute
Subject NKG2D CAR-NK Cell therapy — Other

Indications

acute myeloid leukemia